| Product NDC: | 0074-3956 |
| Proprietary Name: | Kaletra |
| Non Proprietary Name: | Lopinavir and Ritonavir |
| Active Ingredient(s): | 80; 20 mg/mL; mg/mL & nbsp; Lopinavir and Ritonavir |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0074-3956 |
| Labeler Name: | AbbVie Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021251 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20100618 |
| Package NDC: | 0074-3956-46 |
| Package Description: | 160 mL in 1 BOTTLE (0074-3956-46) |
| NDC Code | 0074-3956-46 |
| Proprietary Name | Kaletra |
| Package Description | 160 mL in 1 BOTTLE (0074-3956-46) |
| Product NDC | 0074-3956 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Lopinavir and Ritonavir |
| Dosage Form Name | SOLUTION |
| Route Name | ORAL |
| Start Marketing Date | 20100618 |
| Marketing Category Name | NDA |
| Labeler Name | AbbVie Inc. |
| Substance Name | LOPINAVIR; RITONAVIR |
| Strength Number | 80; 20 |
| Strength Unit | mg/mL; mg/mL |
| Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] |